Understanding Drug Interactions in Chronic Myeloid Leukemia Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial aims to identify and analyze concomitant treatments for patients with Chronic Myeloid Leukemia (CML) who are taking Tyrosine Kinase Inhibitors (TKIs). It focuses on correlating the dosages of these treatments with TKI dosages to ensure effective treatment adherence. If patients show unsatisfactory results, pharmaceutical interventions may be implemented, including changes in treatments or dosages. The study seeks to improve patient outcomes by optimizing treatment regimens based on individual responses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Major patient;
* Patient affiliated to a social security scheme;
* Patient suffering from Chronic Myeloid Leukemia, taking a Tyrosine Kinase Inhibitor (Imatinib, Nilotinib, Dasatinib, or Bosutinib);
* Molecular response \< 4,5 Log;

Exclusion Criteria:

* Legal incapacity or limited capacity ; Medical or psychological incapacity or limited capacity;
* Not able to read and/or to write French;
* Patient taking Ponatinib.

Where it's running

• CHU de Saint-Etienne
  Saint-Etienne, France Recruiting

Study contacts

• Principal investigator: Xavier SIMOENS, MD, PhD — CHU de Saint-Etienne
• Study coordinator: Elisabeth DAGUENET, doctor of science
• Email: elisabeth.daguenet@chu-st-etienne.fr
• Phone: 0477822875

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dasatinib plus ropeginterferon for newly diagnosed chronic myeloid leukemia in chronic phase

  This study tests whether the drug combination dasatinib and ropeginterferon can help control chronic myeloid leukemia in adults with newly diagnosed disease.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07269470

• Prophylactic DLI-X to Prevent Leukemia Relapse After Transplant

  This first-in-human trial tests a prophylactic DLI-X approach to see if it can prevent relapse after matched sibling or haploidentical stem cell transplant in patients with acute leukemias and related blood disorders.

  Recruiting Phase 1 University of Arizona · Tucson, Arizona · NCT07254793

• Optimizing post-transplant bendamustine plus cyclophosphamide for high‑risk myeloid cancers with a partially mismatched donor

  This trial tests whether giving bendamustine plus cyclophosphamide after transplant (with possible abatacept or ruxolitinib) can reduce dangerous cytokine release and graft‑versus‑host disease for people with high‑risk myeloid malignancies who have a partially HLA‑mismatched donor.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT07238712

• CBX-250 for relapsed or refractory myeloid leukemias.

  This will try CBX-250, a new injectable medicine, in people aged 12 and older with relapsed or refractory AML, high-risk MDS, CMML, or CML to see if it can control disease with tolerable side effects.

  Recruiting at 11 sites Phase 1 Crossbow Therapeutics, Inc. · Duarte, California and 10 other locations · NCT06994676

• Olverembatinib monotherapy for adults with newly diagnosed chronic-phase CML

  We are testing whether olverembatinib can control disease and produce deep molecular responses in adults newly diagnosed with chronic-phase CML.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06817720

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.